生物有效剂量预测垂体腺瘤单次放射外科后垂体功能减退
该队列研究纳入2007至2014年接受单次立体定向放射外科(SRS)的97例垂体腺瘤患者,均无既往垂体放疗史、SRS前内分泌功能正常且内分泌随访超过24个月。中位随访48个月时27例(28%)出现新发垂体功能减退,校正性别与腺体体积后,腺体平均BED>45 Gy2.47与平均腺体剂量>10 Gy均与风险升高显著相关。结论认为BED对垂体功能减退的预测较平均腺体剂量更可靠,但需进一步研究确认。
要点
- 单次SRS后中位22个月可出现新发垂体功能减退,5年 actuarial 率达31%。
- 腺体平均BED>45 Gy2.47与平均腺体剂量>10 Gy均显著增加垂体功能减退风险。
- BED对垂体功能减退的预测优于平均腺体剂量,但结论仍需更多研究验证。
核心结论
- 在垂体腺瘤单次SRS后,BED对垂体功能减退的预测较平均腺体剂量更可靠,但需额外研究确认。
研究设计与样本
- 队列研究,纳入2007至2014年接受单次SRS的97例垂体腺瘤患者,要求无既往垂体放疗、SRS前内分泌功能正常且内分泌随访超过24个月。
- 采用Cox比例风险分析评估腺体平均剂量与BED对新发SRS后垂体功能减退的预测价值。
主要发现
- SRS后中位随访48个月(IQR 34-68),27例(28%)出现新发垂体功能减退,中位发生时间22个月(IQR 12-36)。
- 新发内分泌病2年 actuarial 率为17%(95%CI 10%-25%),5年为31%(95%CI 20%-42%)。
- 单因素分析中性别(P=.02)、腺体体积(P=.03)、腺体平均剂量(P<.0001)与BED(P<.0001)均显著预测新发垂体功能减退。
- 校正性别与腺体体积后,BED>45 Gy2.47与平均腺体剂量>10 Gy均与垂体功能减退风险升高显著相关(HR=14.32,95%CI 4.26-89.0,P<.0001;HR=11.91,95%CI 3.54-74.0,P<.0001)。
关键数值与推荐
- BED>45 Gy2.47:校正性别与腺体体积后与垂体功能减退风险升高显著相关(HR=14.32,95%CI 4.26-89.0,P<.0001)。
- 平均腺体剂量>10 Gy:校正性别与腺体体积后与垂体功能减退风险升高显著相关(HR=11.91,95%CI 3.54-74.0,P<.0001)。
临床怎么用
- 单次SRS治疗垂体腺瘤制定剂量计划时,可同时关注腺体平均BED与平均腺体剂量以评估垂体功能减退风险。
- 对腺体平均BED>45 Gy2.47或平均腺体剂量>10 Gy者,应加强SRS后内分泌随访。
局限性
- 作者指出需额外研究确认BED预测价值的结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hypopituitarism is the most frequent complication after pituitary adenoma stereotactic radiosurgery (SRS) and is correlated with increasing radiation to the pituitary gland. Biological effective dose (BED) is a dosimetric parameter that incorporates a time component to adjust for mechanisms of deoxyribonucleic acid repair activated during treatment. OBJECTIVE: To assess mean gland BED as a predictor of post-SRS hypopituitarism, as compared to mean gland dose, in a contemporary cohort study of patients undergoing single-fraction SRS for pituitary adenoma. METHODS: Cohort study of 97 patients undergoing single-fraction SRS from 2007 to 2014. Eligible patients had no prior pituitary irradiation, normal pre-SRS endocrine function, and >24 mo of endocrine follow-up. Cox proportional hazards analysis was used to assess mean gland dose and BED as predictors of new post-SRS hypopituitarism. RESULTS: Median post-SRS follow-up was 48 mo (interquartile range [IQR], 34-68). A total of 27 patients (28%) developed new hypopituitarism at a median 22 mo (IQR, 12-36). Actuarial rates of new endocrinopathy were 17% at 2 yr (95% CI 10%-25%) and 31% at 5 yr (95% CI 20%-42%). On univariate analysis, sex (P = .02), gland volume (P = .03), mean gland dose (P < .0001), and BED significantly predicted new hypopituitarism (P < .0001). After adjusting for sex and gland volume, BED > 45 Gy2.47 and mean gland dose > 10 Gy were significantly associated increased risk of hypopituitarism (hazard ratio [HR] = 14.32, 95% CI = 4.26-89.0, P < .0001; HR = 11.91, 95% CI = 3.54-74.0, P < .0001). CONCLUSION: BED predicted hypopituitarism more reliably than mean gland dose after pituitary adenoma SRS, but additional studies are needed to confirm these results.
引用
- Graffeo CS, Perry A, Link MJ, et al. Biological Effective Dose as a Predictor of Hypopituitarism After Single-Fraction Pituitary Adenoma Radiosurgery: Dosimetric Analysis and Cohort Study of Patients Treated Using Contemporary Techniques. Neurosurgery. 2021. PMID: 33469668. doi:10.1093/neuros/nyaa555
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。